Desvenlafaxine

證據等級: L5

預測適應症: 10 個

Desvenlafaxine: From Major Depressive Disorder to Obsessive-Compulsive Disorder

One-Sentence Summary

Desvenlafaxine (Pristiq) is a serotonin-norepinephrine reuptake inhibitor (SNRI) — the active metabolite of venlafaxine — FDA-approved in the United States for major depressive disorder, though it currently holds no marketing authorisation in Taiwan. The TxGNN model predicts it may be effective for Obsessive-Compulsive Disorder (OCD), with 2 clinical trials and 4 publications currently identified — however, neither trial tested desvenlafaxine as a primary OCD treatment, making all available evidence indirect.

Quick Overview

Item	Content
Original Indication	Major Depressive Disorder (US FDA-approved as Pristiq; no Taiwan licence on record)
Predicted New Indication	Obsessive-Compulsive Disorder
TxGNN Prediction Score	99.91%
Evidence Level	L4
Taiwan Market Status	✗ Not Marketed
Number of NDAs (Taiwan)	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Desvenlafaxine is the major active metabolite of venlafaxine, sharing the same core pharmacology: potent and balanced inhibition of both the serotonin (SERT) and norepinephrine (NET) transporters. Although detailed mechanism-of-action data from DrugBank were not retrieved in this evidence pack, the SNRI classification is well-established in the clinical literature (see PMID 14624187, 24766145, 37032427). Its serotonin reuptake inhibition is particularly pronounced and is considered the primary driver of antidepressant efficacy.

OCD is one of the psychiatric disorders most tightly linked to serotonergic dysregulation, specifically in the cortico-striato-thalamo-cortical (CSTC) circuit. First-line pharmacotherapy consists of SSRIs and the tricyclic clomipramine — both of which work primarily through serotonin reuptake inhibition. SNRIs are a mechanistically logical next step, and critically, venlafaxine — desvenlafaxine’s parent compound — has direct Phase 2/3 RCT evidence in OCD (PMID 14624187), demonstrating comparable efficacy to paroxetine in 150 patients. Since desvenlafaxine is the pharmacologically active form that venlafaxine is converted to in vivo, a class-effect extrapolation is biologically defensible.

That said, desvenlafaxine has not been studied as a primary OCD treatment. NCT03299166 permitted desvenlafaxine as a background therapy while testing troriluzole as an adjunct, and NCT01527786 studied postpartum depression and was misclassified to this indication. The mechanistic case is promising, but the clinical evidence gap between the parent compound (venlafaxine) and desvenlafaxine in OCD remains to be directly bridged.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03299166	Phase 2/3	Completed	426	Randomised double-blind trial of troriluzole vs. placebo as adjunctive therapy in OCD patients with inadequate response to SSRI, clomipramine, venlafaxine, or desvenlafaxine; desvenlafaxine served as an eligible standard background treatment, not the investigational drug — constitutes indirect OCD-setting evidence
NCT01527786	Phase 3	Completed	25	Pilot study of functional outcomes in postpartum depression treated with desvenlafaxine; not an OCD trial — classified here due to PPD–OCD comorbidity literature linkage, not primary indication relevance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14624187	2003	RCT	Journal of Clinical Psychopharmacology	First double-blind RCT comparing an SNRI (venlafaxine) vs. paroxetine in 150 OCD patients; venlafaxine showed comparable efficacy — the most directly relevant proxy evidence for desvenlafaxine’s potential in OCD via class effect
24766145	2014	Review	Expert Opinion on Pharmacotherapy	Updated review of double-blind trials testing serotonergic antidepressants in OCD, including SNRI data; contextualises the mechanistic rationale for the 5-HT agent class in OCD pharmacotherapy
36686097	2022	Review	Cureus	Comprehensive review of postpartum depression noting that OCD can emerge as a downstream complication of PPD; limited direct relevance to desvenlafaxine–OCD efficacy
40224942	2025	Clinical Study	Psychiatry and Clinical Psychopharmacology	Risperidone augmentation in antidepressant-resistant somatic symptom disorder, mentioning OCD augmentation context incidentally; peripheral relevance to desvenlafaxine–OCD

Taiwan Market Information

Desvenlafaxine is not licensed or marketed in Taiwan. No TFDA New Drug Applications (NDAs) were found in the regulatory database as of the data cutoff (2026-06-21).

Note: Desvenlafaxine is FDA-approved in the United States under the brand name Pristiq (Pfizer) for the treatment of major depressive disorder in adults, as confirmed by clinical trial references (NCT01537068 brief summary: “Desvenlafaxine [trade name Pristiq] has been approved by the FDA for the treatment of major depression”).

Safety Considerations

Please refer to the package insert for safety information.

TFDA package insert data were not retrieved in this evidence pack (Data Gap DG001: Blocking severity). US FDA label for Pristiq should be consulted for warnings, contraindications, and drug interaction profiles before any clinical use or protocol design.

Conclusion and Next Steps

Decision: Hold

Rationale: No clinical trial has directly tested desvenlafaxine as a primary treatment for OCD; the strongest mechanistic link runs through venlafaxine (parent compound) rather than desvenlafaxine itself, and current evidence does not meet the minimum threshold for advancing to a formal repurposing evaluation. The L4 evidence classification reflects preclinical/mechanism-level support only.

To proceed, the following is needed:

A dedicated Phase 2 pilot RCT or open-label study evaluating desvenlafaxine monotherapy or augmentation specifically in OCD patients
Retrieval and parsing of the US FDA Pristiq label (and TFDA application if pursued) to document key warnings, contraindications, and drug interactions
DrugBank API query to obtain complete MOA data, including receptor binding affinities and transporter selectivity profile
Targeted literature search for desvenlafaxine (not venlafaxine as proxy) in OCD — including case series, naturalistic studies, and pharmacovigilance signals
Drug interaction assessment for OCD co-medications commonly used alongside SNRIs (clomipramine, atypical antipsychotics, benzodiazepines)
TFDA marketing authorisation pathway assessment, given current 未上市 status in Taiwan

💡 Higher-priority candidates identified in this evidence pack: The dysthymic disorder indication (Rank 8, L3 evidence, 3 direct clinical trials including a Phase 4 RCT) and melancholia/MDD indication (Rank 10, L2 evidence, 19 publications including multiple meta-analyses and a head-to-head RCT) both carry substantially stronger evidence bases and are recommended as higher-priority targets for accelerated evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.